Table of Contents Author Guidelines Submit a Manuscript
Infectious Diseases in Obstetrics and Gynecology
Volume 2018, Article ID 7040498, 10 pages
https://doi.org/10.1155/2018/7040498
Research Article

Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant Candida albicans and Non-albicans Candida Species

Cidara Therapeutics, Inc., San Diego, CA, USA

Correspondence should be addressed to Jeffrey B. Locke; moc.aradic@ekcolj

Received 12 July 2017; Accepted 17 January 2018; Published 22 February 2018

Academic Editor: Bryan Larsen

Copyright © 2018 Jeffrey B. Locke et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. D. Sobel, S. Faro, R. W. Force et al., “Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations,” American Journal of Obstetrics & Gynecology, vol. 178, no. 2, pp. 203–211, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Foxman, R. Muraglia, J.-P. Dietz, J. D. Sobel, and J. Wagner, “Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey,” Journal of Lower Genital Tract Disease, vol. 17, no. 3, pp. 340–345, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Foxman, R. Barlow, H. D'Arcy, B. Gillespie, and J. D. Sobel, “Candida vaginitis: self-reported incidence and associated costs,” Sexually Transmitted Diseases, vol. 27, no. 4, pp. 230–235, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. J. M. Achkar and B. C. Fries, “Candida infections of the genitourinary tract,” Clinical Microbiology Reviews, vol. 23, no. 2, pp. 253–273, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Spinillo, E. Capuzzo, R. Gulminetti, P. Marone, L. Colonna, and G. Piazzi, “Prevalence of and risk factors for fungal vaginitis caused by non-albicans species,” American Journal of Obstetrics & Gynecology, vol. 176, no. 1, pp. 138–141, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. W. Chaim, M. Mazor, and J. D. Sobel, “Candida albicans vulvovaginitis--trends in care and implications,” Harefuah, vol. 133, no. 1-2, pp. 40–43, 1997. View at Google Scholar · View at Scopus
  7. J. D. Mintz and M. G. Martens, “Prevalence of non-albicans Candida infections in women with recurrent vulvovaginal symptomatology,” Advances in Infectious Diseases, vol. 03, no. 04, pp. 238–242, 2013. View at Publisher · View at Google Scholar
  8. S. S. Richter, R. P. Galask, S. A. Messer, R. J. Hollis, D. J. Diekema, and M. A. Pfaller, “Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases,” Journal of Clinical Microbiology, vol. 43, no. 5, pp. 2155–2162, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Marchaim, L. Lemanek, S. Bheemreddy, K. S. Kaye, and J. D. Sobel, “Fluconazole-resistant candida albicans vulvovaginitis,” Obstetrics & Gynecology, vol. 120, no. 6, pp. 1407–1414, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. Z. Shahid and J. D. Sobel, “Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy,” Diagnostic Microbiology and Infectious Disease, vol. 64, no. 3, pp. 354–356, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Mølgaard-Nielsen, H. Svanström, M. Melbye, A. Hviid, and B. Pasternak, “Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth,” Journal of the American Medical Association, vol. 315, no. 1, pp. 58–67, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. J. D. Sobel, “Recurrent vulvovaginal candidiasis,” American Journal of Obstetrics & Gynecology, vol. 214, no. 1, pp. 15–21, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Faro, “Systemic vs. topical therapy for the treatment of vulvovaginal candidiasis,” Infectious Diseases in Obstetrics and Gynecology, vol. 1, no. 4, pp. 202–208, 1994. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Aballéa, F. Guelfucci, J. Wagner et al., “Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA,” Health and Quality of Life Outcomes, vol. 11, no. 1, article 169, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. Y.-X. Zhu, T. Li, S.-R. Fan, X.-P. Liu, Y.-H. Liang, and P. Liu, “Health-related quality of life as measured with the Short-Form 36 (SF-36) questionnaire in patients with recurrent vulvovaginal candidiasis,” Health and Quality of Life Outcomes, vol. 14, no. 1, article 65, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. D. S. Perlin, “Current perspectives on echinocandin class drugs,” Future Microbiology, vol. 6, no. 4, pp. 441–457, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. M. A. Pfaller, S. A. Messer, P. R. Rhomberg, and M. Castanheira, “Activity of a long-acting echinocandin (CD101) and seven comparator antifungal agents tested against a global collection of contemporary invasive fungal isolates in the SENTRY 2014 Antifungal Surveillance Program,” Antimicrobial Agents and Chemotherapy, vol. 61, no. 3, Article ID e02045, 2017. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Hall, R. Bonifas, L. Stapert, M. Thwaites, D. L. Shinabarger, and C. M. Pillar, “In vitro potency and fungicidal activity of CD101, a novel echinocandin, against recent clinical isolates of Candida spp.,” Diagnostic Microbiology and Infectious Disease, vol. 89, no. 3, pp. 205–211, 2017. View at Publisher · View at Google Scholar · View at Scopus
  19. M. A. Pfaller, S. A. Messer, P. R. Rhomberg, R. N. Jones, and M. Castanheira, “Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates,” Journal of Antimicrobial Chemotherapy, vol. 71, no. 10, Article ID dkw214, pp. 2868–2873, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. D. A. Boikov, J. B. Locke, K. D. James, K. Bartizal, and J. D. Sobel, “In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis,” Journal of Antimicrobial Chemotherapy, vol. 72, no. 5, pp. 1355–1358, 2017. View at Publisher · View at Google Scholar · View at Scopus
  21. CLSI, M27-S4, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Fourth informational supplement, Clinical and Laboratory Standards Institute, Pennsylvania, Pa, USA, 2012.
  22. M.-Y. S. Moosa, J. D. Sobel, H. Elhalis, W. Du, and R. A. Akins, “Fungicidal activity of Fluconazole against Candida albicans in a synthetic vagina-simulative medium,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 1, pp. 161–167, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. CLSI, M27-A3, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Approved Standard, Clinical and Laboratory Standards Institute, Pennsylvania, Pa, USA, 3rd edition, 2008.
  24. M. E. Klepser et al., “Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans,” Antimicrobial Agents and Chemotherapy, vol. 41, no. 6, pp. 1392–1395, 1997. View at Google Scholar
  25. M. A. Pfaller et al., Activity of a Long-Acting Echinocandin (CD101) and Comparator Antifungal Agents Tested Against Contemporary Worldwide Invasive Fungal Isolates, IDWeek, Louisiana, La, USA, 2016.
  26. C. S. Danby, D. Boikov, R. Rautemaa-Richardson, and J. D. Sobel, “Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use,” Antimicrobial Agents and Chemotherapy, vol. 56, no. 3, pp. 1403–1406, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. W. Liu et al., “Impact of pH on the antifungal susceptibility of vaginal Candida albicans,” International Journal of Gynecology and Obstetrics, vol. 114, no. 3, pp. 278–280, 2011. View at Google Scholar
  28. V. Ong et al., “Optimization of CD101 Formulation against Candida albicans in a Rat Model of Vulvovaginal Candidiasis (VVC),” in Proceedings of the ASM Microbe 2016, 2016.
  29. C. J. Clancy, H. Huang, S. Cheng, H. Derendorf, and M. H. Nguyen, “Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 7, pp. 2569–2572, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Li, M. H. Nguyen, H. Derendorf, S. Cheng, and C. J. Clancy, “Measurement of voriconazole activity against Candida albicans, C. glabrata, and C. parapsilosis isolates using time-kill methods validated by high-performance liquid chromatography,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 8, pp. 2985–2987, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Fernandez-Ruiz et al., “Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis,” Clinical Infectious Diseases, vol. 58, no. 10, pp. 1413–1421, 2014. View at Google Scholar
  32. J. L. Thomason, “Clinical evaluation of terconazole. United states experience,” J Reprod Med, vol. 34, no. 8 Suppl, pp. 597–601, 1989. View at Google Scholar
  33. G. P. Bodey, “Azole antifungal agents,” Clinical Infectious Diseases, vol. 14, pp. S161–S169, 1992. View at Publisher · View at Google Scholar · View at Scopus
  34. Cidara Therapeutics Reports Unfavorable Results of Phase 2 RADIANT Trial of CD101 Topical in VVC, 2017, http://ir.cidara.com/phoenix.zhtml?c=253962&p=irol-newsArticle&ID=2247615.
  35. C. A. Muzny and J. R. Schwebke, “Biofilms: an underappreciated mechanism of treatment failure and recurrence in vaginal infections,” Clinical Infectious Diseases, vol. 61, no. 4, pp. 601–606, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. J. D. Sobel, “Editorial Commentary: Vaginal Biofilm: Much Ado about Nothing, or a New Therapeutic Challenge?” Clinical Infectious Diseases, vol. 61, no. 4, pp. 607-608, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Gonçalves, C. Ferreira, C. T. Alves, M. Henriques, J. Azeredo, and S. Silva, “Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors,” Critical Reviews in Microbiology, vol. 42, no. 6, pp. 905–927, 2016. View at Publisher · View at Google Scholar · View at Scopus